JAZZ Jazz Pharmaceuticals plc

Price (delayed)

$156.3

Market cap

$9.74B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.48

Enterprise value

$15.36B

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration ...

Highlights
The revenue has grown by 35% YoY and by 7% from the previous quarter
The gross profit has grown by 22% YoY and by 4.9% from the previous quarter
Jazz Pharmaceuticals's net income has shrunk by 187% YoY and by 36% QoQ
The company's EPS has shrunk by 181% YoY and by 36% QoQ

Key stats

What are the main financial stats of JAZZ
Market
Shares outstanding
62.32M
Market cap
$9.74B
Enterprise value
$15.36B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.67
Price to sales (P/S)
2.93
EV/EBIT
216.73
EV/EBITDA
21.03
EV/Sales
4.65
Earnings
Revenue
$3.3B
EBIT
$70.85M
EBITDA
$730.08M
Free cash flow
$664.72M
Per share
EPS
-$7.48
Free cash flow per share
$10.74
Book value per share
$58.45
Revenue per share
$53.35
TBVPS
$51.78
Balance sheet
Total assets
$11.77B
Total liabilities
$8.16B
Debt
$6.11B
Equity
$3.61B
Working capital
$1.76B
Liquidity
Debt to equity
1.69
Current ratio
3.39
Quick ratio
1.44
Net debt/EBITDA
7.69
Margins
EBITDA margin
22.1%
Gross margin
84.4%
Net margin
-13.6%
Operating margin
2.9%
Efficiency
Return on assets
-3.6%
Return on equity
-11.5%
Return on invested capital
0.9%
Return on capital employed
0.6%
Return on sales
2.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
0.68%
1 week
4.86%
1 month
3.57%
1 year
-12.7%
YTD
22.68%
QTD
0.4%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$3.3B
Gross profit
$2.78B
Operating income
$95.71M
Net income
-$449.85M
Gross margin
84.4%
Net margin
-13.6%
Jazz Pharmaceuticals's net income has shrunk by 187% YoY and by 36% QoQ
The company's net margin has shrunk by 164% YoY and by 27% QoQ
JAZZ's operating margin has dropped by 90% year-on-year and by 47% since the previous quarter
The operating income has dropped by 87% year-on-year and by 44% since the previous quarter

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.67
P/S
2.93
EV/EBIT
216.73
EV/EBITDA
21.03
EV/Sales
4.65
The company's EPS has shrunk by 181% YoY and by 36% QoQ
The price to book (P/B) is 16% higher than the last 4 quarters average of 2.3
Jazz Pharmaceuticals's equity has decreased by 9% from the previous quarter and by 5% YoY
The revenue has grown by 35% YoY and by 7% from the previous quarter
The price to sales (P/S) is 29% less than the 5-year quarterly average of 4.1 and 3% less than the last 4 quarters average of 3.0

Efficiency

How efficient is Jazz Pharmaceuticals business performance
The return on equity has dropped by 178% year-on-year and by 39% since the previous quarter
The company's return on assets has shrunk by 144% YoY and by 24% QoQ
JAZZ's ROIC has shrunk by 95% YoY and by 61% QoQ
The company's return on sales has shrunk by 93% YoY and by 60% QoQ

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 44% greater than the total liabilities
JAZZ's total liabilities has soared by 176% year-on-year but it is down by 2.1% since the previous quarter
The total assets has soared by 74% year-on-year but it is down by 4.3% since the previous quarter
The company's debt is 69% higher than its equity
Jazz Pharmaceuticals's debt to equity has surged by 186% YoY and by 9% QoQ
The company's debt has surged by 173% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.